Cascade screening for familial hypercholesterolaemia: Implications of a pilot study for national screening programmes

Journal of Medical Screening

Volumn 13, Issue 3, 2006, Pages 156-159

  Marks, D ^b   Thorogood, M ^c   Neil, S M ^a   Humphries, S E ^d   Neil, H A W ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FAMILIAL HYPERCHOLESTEROLEMIA; GENERAL PRACTITIONER; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; MEDICAL SPECIALIST; NURSE; PATIENT ATTITUDE; PATIENT CARE PLANNING; POPULATION RESEARCH; PREVALENCE; RELATIVE; UNITED KINGDOM;

ADULT; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MASS SCREENING; PILOT PROJECTS; PREVALENCE;

EID: 33749010343     PISSN: 09691413     EISSN: 09691413     Source Type: Journal    
DOI: 10.1258/096914106778440617     Document Type: Article

References (25)

1. Neil HAW, Hammond T, Huxley R, et al. The extent of under-diagnosis of familial hypercholesterolaemia in routine practice: results of a prospective register study. BMJ 2000;321:148
2. Marks D, Thorogood M, Farrer JM, et al. Census of clinics providing specialist lipid services in the UK. J Publ Health 2004;26:353-4
3. Goldstein JL, Hobbs HH, Brown MS. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 8th edn. New York: McGraw-Hill, 1995;1981-2030
4. Humphries SE, 2001. www.ucl.ac.uk/fh/
5. Tybjaerg-Hansen A, Gallagher J, Vincent J, et al. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990;80:235-42
6. Humphries SE, Whittall R, Hubbard C, et al., for the Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in UK patients and relation with plasma lipid levels and coronary heart disease risk. J Med Genet 2006, [Epub ahead of print]: PMID 16801348
7. Scientific Steering Committee on behalf of Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6
8. Scientific Steering Committee on behalf of Simon Broome Familial Hyperlipidaemia Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for patient management. Atherosclerosis 1999;142:105-12
9. Kaste M, Koivisto P. Risk of brain infarction in familial hypercholesterolaemia. Stroke 1988;19:1097-100
10. Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinaemia. Circulation 1974;49:476-88
11. Slack J. Risks of ischaemic heart disease in familial hyperlipidaemic states. Lancet 1969;ii:1380-2
12. Dorsch MF, Lawrence RA, Durham NP, et al. Familial hypercholesterolaemia is underdiagnosed after AMI. BMJ 2001;322:111
13. Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first degree relatives. Lancet 1972;i:393-9
14. Marks D, Wonderling D, Thorogood M, et al. Cost-effectiveness of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303-8
15. Bhatnagar D, Morgan J, Siddiq S, et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000;321:1-5
16. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, et al. Review of first 5 years of screening for familial hypercholesterolaemia. Lancet 2001;357:165-8
17. Batki Ad, Holder R, Thomason HL, et al. Evaluation of the Cholestech LDX analyser. Medical Devices Agency evaluation report 1995
18. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolaemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6
19. Key population and vital statistics. Local and Health Authority Areas. London: The Stationary Office, 2003
20. Kwiterovich Jnr PO, Fredrickson DS, Levy RI. Familial hypercholesterolaemia (one form of type II hyperlipoproteinaemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest 1974;53:1237-49
21. Leonard JV, Whitelaw AG, Wolff OH, et al. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. BMJ 1977;1:1566-8
22. Weigeman A, Rodenburg J, de Jongh S, et al. Family History and cardiovascular risk in familial hyperchoelsterolaemia. Circulation 2003;107:1473-8
23. Graham CA, McClean E, Ward AJM, et al. Mutation screening and genotype: phenotype correlation in familial hypercholesterolaemia. Atherosclerosis 1999;147:309-16
24. Bellis MA, Hughes K, Hughes, et al. Measuring paternal discrepancy and its public health consequences. J Epidemiol Commun Health 2005;59:749-54
25. Newson AJ, Humphries SE. Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet 2005;13:401-8